Prostate cancer is the second highest cause of cancerrelated deaths of men in the US. Signal transducers and activators of transcription (STATs) proteins are a small family of latent cytoplasmic transcription factors that act downstream of Janus kinase (JAK) activation and mediate intracellular signaling from a wide variety of cytokines, growth factors, and hormones. Aberrant activation of STAT3 has been implicated in the progression of many human carcinomas, including prostate cancer. Previously, we have characterized a novel tyrosine kinase inhibitor peptide, Tkip, that is a mimetic of suppressor of cytokine signaling 1 (SOCS-1). Similar to SOCS-1, Tkip binds to the autophosphorylation site of JAK2 and inhibits phosphorylation of STAT1a. In this study, we determined the inhibitory effects of Tkip on the human prostate cancer cell lines DU145 and LNCaP. Tkip inhibited cellular proliferation of both DU145 and LNCaP cells, with a slightly greater antiproliferative effect on DU145 cells. Cell cycle analysis using flow cytometry showed Tkip blockage of progression into the S phase of the cell cycle. Tkip also inhibited constitutive (DU145) and IL-6-induced (LNCaP) activation of STAT3, consistent with the fact that STAT3 activation is mediated by JAK2. Tkip also slightly reduced the levels of cyclin D1, an important regulator of cell cycle progression into S phase, in DU145 and LNCaP cancer cell lines. These data describe a potentially important therapeutic that targets both constitutive and IL-6-induced STAT3 activation in human prostate cancer cell lines.
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Oncogene ( Prostate cancer is the second leading cause of cancer deaths among men (Crawford, 2003) . At the initial stages of disseminated disease, tumors generally regress following androgen ablation, but progressive disease invariably returns with refractiveness to further androgen depletion (De La Taille et al., 2001; Deutsch et al., 2004) . Thus, early in the disease prostate cancer cells appear to be androgen-sensitive, but later in the refractive state they become androgen-independent. Interestingly, even in the androgen-independent state the growth of prostate cancer cells may depend on the androgen receptor signaling pathway (Culig et al., 1994; Nazareth and Weigel, 1996; Sadar, 1999; Chen et al., 2000; Shi et al., 2004) . It has been proposed that the androgen receptor signaling pathway in treatmentresistant prostate tumors is activated by nonsteriodal factors such as the cytokine interleukin 6 (IL-6) and growth factors such as epidermal growth factor (EGF) (Culig et al., 1994; Hobisch et al., 1998; Chen et al., 2000; Lorenzo et al., 2003) . This results in activation of Janus kinase 2 (JAK2), which mediates IL-6 activation of transcription factor STAT3 (Kisseleva et al., 2002; Heinrich et al., 2003) . STAT3 is also activated by autophosphorylated EGF receptor (EGFR) (Kisseleva et al., 2002; Chan et al., 2004) . Previous studies regarding the effects of IL-6 on LNCaP cells have produced contradictory results. Several studies have reported that treatment with IL-6 increases cell proliferation (Okamoto et al., 1997; Giri et al., 2001; Ueda et al., 2002) . Conversely, many studies have demonstrated an inhibitory effect of IL-6 on LNCaP cell proliferation (Ritchie et al., 1997; Hobisch et al., 1998; Chung et al., 1999) . Moreover, contradictory results exist for EGF effects on androgen receptor activation. Several reports demonstrate EGF-induced activation of the androgen receptor (Culig et al., 1994) , while other reports suggest that EGF does not activate the androgen receptor (Ueda et al., 2002; Petre-Draviam et al., 2003; Gregory et al., 2004) . Thus, the effects of cytokines such as IL-6 on prostate cancer cells may be complex and involve yet to be discovered regulatory variables.
Considerable evidence suggests that activated STAT3 functions as an oncogenic protein in a variety of cancers including prostate cancers (Bromberg et al., 1999; Dhir et al., 2002; Calo et al., 2003; Barton et al., 2004) . Androgen-independent DU145 cancer cell lines, for example, constitutively express activated STAT3 as a result of autocrine production of IL-6, while androgensensitive LNCaP prostate cancer cell lines show paracrine IL-6 activation of STAT3 (Okamoto et al., 1997; Smith et al., 2001; Mora et al., 2002) . It has been shown that IL-6-induced proliferation of these cancer cell lines is associated with activation of STAT3, and that inhibition of IL-6 activation of STAT3 results in inhibition of cell growth as well as induction of apoptosis (Mora et al., 2002; Barton et al., 2004) .
The activity of tyrosine kinases such as JAK2 and EGFR are negatively regulated by members of the suppressors of cytokine signaling family or SOCS (reviewed in Larsen and Ropke, 2002; Alexander and Hilton, 2004) . These inducible proteins are of significantly variable lengths, but share domains of homology that characterize the family and its function (Larsen and Ropke, 2002; Alexander and Hilton, 2004) . Currently, there are eight identified members of the SOCS family, SOCS-1 through SOCS-7 and CIS. SOCS-1 and SOCS-3 are of particular interest as possible regulators of cancer as they are negative regulators of both JAK2 and EGFR (Larsen and Ropke, 2002; Xia et al., 2002; Alexander and Hilton, 2004) . Structure-function studies using truncated versions of SOCS-1 have identified the regions that are essential for SOCS-JAK2 association and for inhibition of JAK2 activity. Tyrosine-phosphorylated JAK2 and STAT are greatly reduced following expression of SOCS-1 (Yasukawa et al., 1999; Larsen and Ropke, 2002; Alexander and Hilton, 2004) , suggesting that SOCS-1 inhibits tyrosine kinase activity upon interaction with JAK2.
We previously developed a short 12-mer peptide mimetic of SOCS-1, WLVFFVIFYFFR (Tkip) , that binds to the autophosphorylation site of JAK2, resulting in inhibition of its autophosphorylation as well as its phosphorylation of gamma interferon (IFNg) receptor subunit IFNGR-1 (Flowers et al., 2004) . Intracellular delivery of Tkip via a lipophilic (N-terminal palmitylated) derivative inhibited IFNg antiviral activity and IFNg-mediated induction of MHC Class I (Flowers et al., 2004) . It was also demonstrated that Tkip inhibits the autophosphorylation of EGFR by an unknown mechanism using in vitro kinase assays. Based on the fact that Tkip inhibits both JAK2 and EGFR autophosphorylation, it is not possible to attribute Tkip inhibition of biological activity as being strictly due to inhibition of JAK2 tyrosine kinase activity. Data are presented in this study demonstrating Tkip inhibition of DU145 and LNCaP cancer cell growth at the G 0 /G 1 to S transition of the cell cycle. We also show that the Tkip SOCS-1 peptide mimetic inhibits both constitutive and IL-6-induced activation of STAT3 in prostate cancer cells. The results of this study indicate a novel approach to regulation of cancer cells via regulation of tyrosine kinase activity at the autophosphorylation site using a SOCS-1 peptide mimetic.
To determine the antiproliferative effect of Tkip in prostate cancer cell lines, DU145 (androgen-independent) and LNCaP (androgen-sensitive) cells were incubated in the absence of serum for 24 h and treated with varying doses of lipophilic Tkip and lipophilic control peptide, MuIFNg(95-125) (see Table 1 for sequences) in growth media containing 10% serum for 48 h. Percent inhibition was determined by direct cell counts using light microscopy following treatment with the exclusion dye trypan blue (Figure 1 Table 2 . DU145 (20.170.3 mM) cells are more sensitive to Tkip treatment compared to LNCaP in the absence (29.270.5 mM) and presence (34.670.2 mM) of IL-6. Cells treated with IL-6 showed a modest 20% increase in numbers after 48 h and had a slightly higher IC 50 for Tkip. Thus, Tkip had a slightly greater antiproliferative effect on DU145 cells. Treatment of prostate cancer cells with lipophilic control peptide had no significant effect on cell growth at any of the concentrations used in the proliferation assay. The percent viability for all cell lines was greater than 95% by trypan blue exclusion, and thus growth inhibition was not due to cytotoxicity. These results indicate that Tkip inhibits the growth of prostate cancer cell lines DU145 and LNCaP in a concentration-dependent manner.
We next determined the effect of the SOCS-1 mimetic on the cell cycle of DU145 (Table 3) and LNCaP (Table 4) cells. DU145 cells synchronized by serum starvation into G 0 /G 1 were stimulated to enter the cell cycle by serum addition in the presence or absence of 1-10 mM final concentrations of lipophilic Tkip (Flowers et al., 2004) . Untreated cells and cells treated with lipophilic control peptide showed 30.6% each of cells in the S phase of the cell cycle at 24 h. Cells treated with 5 and 10 mM of Tkip showed 29.8 and 16.4%, respectively, of cells in the S phase of the cell cycle. Thus, Tkip inhibited movement of DU145 from G 0 /G 1 to the S phase of the cell cycle. Tkip similarly inhibited cell cycling of LNCaP cells where untreated and control peptide showed 28.1 and 29.3% of the cells, respectively, in the S phase, while 5 and 10 mM of Tkip-treated cells showed 19.8 and 16.4%, respectively, of cells in the S phase of the cell cycle. Thus, Tkip inhibits both androgen-independent and androgen-sensitive prostate cancer cell line movement from G 0 /G 1 to the S phase of the cell cycle.
DU145 cells have constitutively activated or phosphorylated STAT3 that involves JAK2 as a result of autocrine production of IL-6 (Okamoto et al., 1997; Mora et al., 2002; Barton et al., 2004) . DU145 cells were therefore treated with 1-8 mM lipophilic Tkip as shown in Figure 2a , and constitutive phosphorylation of The peptides used in this study were synthesized in our laboratory using conventional fluorenylmethyloxycarbonyl (Fmoc) chemistry as described previously (Szente et al., 1996; Flowers et al., 2004) . A lipophilic group (palmitoyl-lysine) was added to the N-terminus of the synthetic peptides during peptide synthesis to enhance cellular uptake (Thiam et al., 1999) STAT3 was determined. Tkip completely inhibited STAT3 phosphorylation at a concentration as low as 5 mM. Control lipophilic peptides failed to inhibit constitutive phosphorylation of STAT3 (Figure 2a ). To confirm whether control peptides of similar length to Tkip had any effect on STAT3 activation in prostate cancer cell lines, cells were also treated with LipoMuIFNg(95-106) control peptide and analyzed under the same conditions as Tkip. As shown in Figure 2b , Lipo-MuIFNg(95-106) had no effect on STAT3 activation. Thus, Tkip specifically inhibited constitutive STAT3 activation in DU145 prostate cancer cells.
LNCaP cells have been reported to express constitutively activated STAT3 (Giri et al., 2001) as well as to not express constitutively activated STAT3 (Mora et al., 2002) . We have not observed constitutive activation of STAT3 in LNCaP cells under conditions where DU145 cells showed constitutive STAT3 phosphorylation. We therefore treated LNCaP cells with various concentrations were cultured in Eagle's minimum essential medium (EMEM, JHR Biosciences, Lenexa, KS, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA), 100 U/ ml penicillin, and 100 mg/ml streptomycin (complete medium) in tissue culture plates at 371C in a 5% CO 2 atmosphere. LNCaP cells (5 Â 10 4 ) were cultured in RPMI 1640 supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin (complete medium) in six-or 12-well tissue culture plates at 371C in a 5% CO 2 atmosphere. Serum-depleted medium contained EMEM or RPMI 1640 without antibiotics or serum. Cells were plated (1 Â 10 5 cells/ well) in 12-well plates. Following serum-depletion (24 h), cells were incubated with various concentrations of lipophilic Tkip (LipoTkip) or lipophilic control peptides (Lipo-MuIFNg(95-125)) (0 mM, 1 mM, 3 mM, 6 mM, 12 mM, 25 mM, 50 mM) and IL-6 (10 ng/ml) for 48 h. Following incubation, cells were trypsinized, centrifuged, and resuspended in 100 ml of complete media. Live cells were then enumerated directly using a hemocytometer under a light microscope. Cell viability was assessed using trypan blue exclusion (0.4%, Invitrogen, Carlsbad, CA, USA). Trypan blue dye exclusion is a test of plasma membrane physical integrity. Results are plotted as percent inhibition compared to untreated cells after 48 h of culture (1.45 Â 10 5 DU145 cells or 1.25 Â 10 5 LNCaP cells) and IL-6 alone-treated cells (1.5 Â 10 5 cells). Data from representative experiments performed in triplicate are expressed as the mean7 standard deviation ) were incubated in serum-depleted medium for 48 h at 371C in a 5% CO 2 atmosphere to allow cellular synchronization in the G 0 /G 1 phase of the cell cycle. DU145 cells were then treated for an additional 24 h at 371C with complete media in the presence or absence of lipophilic Tkip or lipophilic control peptides. Following treatment, cells were washed twice with ice-cold PBS and harvested by trypsinization for 5 min. Trypsin was then neutralized with the addition of complete growth media in each well. DU145 cells were collected in 5-ml round bottom polystyrene tubes (Fisher, Pittsburgh, PA, USA) and washed three times with PBS and resuspended in 100 ml of sample buffer (1% glucose in PBS). Cells were fixed in 1 ml of ice-cold ethanol and stored for 24-48 h at 41C until stained. DU145 cells were subsequently washed three times with sample buffer to remove ethanol and resuspended in sample buffer containing 45 mg/ml propidium iodide solution and 45 U/ml RNase A (Sigma, St Louis, MO, USA). Cells were incubated for 1 h at room temperature and analyzed (10 000 events) by FACS analysis on a FACSort (Becton Dickinson, San Jose, CA, USA). Flow cytometry data were analyzed using ModFit LTt software (Topsham, ME, USA). Cell viability was greater than 95% based on trypan blue exclusion (data not shown). Data are representative of at least two independent experiments of IL-6 and observed optimal STAT3 phosphorylation at 10 ng/ml as shown in Figure 2c . Tkip at 10 mM inhibited IL-6-induced phosphorylation of STAT3. The lipophilic control peptides, including the MuIFNg (95-106) did not block STAT3 phosphorylation (Figure 2d ). Thus, Tkip specifically inhibited constitutive STAT3 phosphorylation in DU145 cells as well as IL-6-induced phosphorylation of STAT3 in LNCaP cells.
Given that Tkip inhibits both JAK2 and EGFR tyrosine phosphorylations (Flowers et al., 2004) , we next looked at the effect of Tkip on global tyrosine phosphorylation in DU145 and LNCaP cells treated with lipophilic Tkip in 20 h cultures. As can be seen in Figure 3a , untreated DU145 cells contained multiple phosphotyrosine proteins over a wide molecular weight range as determined by Western blot analysis of wholecell lysate gels with antiphosphotyrosine antibody (4G10). Treatment of cells with 1-8 mM Tkip for 20 h showed a dose-response decrease in tyrosine phosphorylated proteins over the entire molecular range. Control peptide MuIFNg(95-125) at 8 mM had no effect on the level of phosphotyrosine proteins. Thus, consistent with the JAK2 and EGFR inhibitory effects of Tkip, extensive inhibition of phosphotyrosine protein phosphorylation was observed in DU145 prostate cancer cells.
LNCaP prostate cancer cells also showed multiple tyrosine kinase phosphorylation of proteins as shown in Figure 3b . The phosphorylation of both untreated and IL-6-treated cells was inhibited by treatment of the cells with 8 mM Tkip, similar to the inhibition of tyrosine phosphorylation of proteins in DU145 cells. The 20 h experiments did not show any toxicity by Tkip as per Flow cytometric analysis was performed as previously described with minor modifications (Hobeika et al., 1998) . LNCaP cells (1 Â 10 6 ) were incubated in serum-depleted medium for 48 h at 371C in a 5% CO 2 atmosphere to allow cellular synchronization in the G 0 /G 1 phase of the cell cycle. LNCaP cells were then treated for an additional 24 h at 371C with complete media in the presence or absence of lipophilic Tkip or lipophilic control peptides. Following treatment, cells were washed twice with ice-cold PBS and harvested by trypsinisation for 5 min. Trypsin was then neutralised with the addition of complete growth media in each well. LNCaP cells were collected in 5-ml round bottom polystyrene tubes (Fisher, Pittsburgh, PA, USA) and washed three times with PBS and resuspended in 100 ml of sample buffer (1% glucose in PBS). Cells were fixed in 1 ml of ice-cold ethanol and stored for 24-48 h at 41C until stained. LNCaP cells were subsequently washed three times with sample buffer to remove ethanol and resuspended in sample buffer containing 45 mg/ml propidium iodide solution and 45 U/ml RNase A (Sigma, St Louis, MO, USA). Cells were incubated for 1 h at room temperature and analyzed (10 000 events) by FACS analysis on a FACSort (Becton Dickinson, San Jose, CA, USA). Flow cytometry data were analyzed using ModFit LTt software (Topsham, ME, USA). Cell viability was greater than 95% based on trypan blue exclusion (data not shown). Data are representative of at least two independent experiments Following incubation, whole-cell lysates were prepared as previously described (Flowers et al., 2004) . Phosphorylated STAT3 expression was examined by incubating nitrocellulose membranes with polyclonal antibodies to tyrosine-phosphorylated STAT3 (Cell Signaling Technologies, Beverly, MA, USA) phosphorylated at Y705 (1 : 1000). Determination of equal protein loading was performed by probing membranes for STAT3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1 : 1000) after stripping membrane. Data are representative of two independent experiments. (d) LNCaP cells were treated in the presence or absence of lipophilic Tkip (Lipo-Tkip; 10 mM, 25mM) or lipophilic control peptides and ; 10 mM, 25 mM) for 20 h and IL-6 (10 ng/ml) for 15 or 30 min. Cell lysates were Western blotted with polyclonal antibodies specific for phosphorylated STAT3 (Y705) trypan blue exclusion (data not shown). The tyrosine kinase inhibition effects of Tkip on prostate cancer cells is consistent with Tkip inhibition of prostate cancer cell growth (Figure 1 ) and data on cell cycling as shown in Tables 3 and 4 . Data in Figure 3b also show constitutive phosphorylation of a protein corresponding to STAT3 activation as per molecular weight markers (arrowhead, top panel) following Western blot analysis with antiphosphotyrosine monoclonal antibodies. Interestingly, following stripping and reprobing with an antibody specific for STAT3 phosphorylated on Y705, constitutive STAT3 activation was absent, but was induced by IL-6 treatment (middle panel, Figure 3b ). STAT3 has also been shown previously to be phosphorylated on Y176, and this may account for possible constitutive tyrosine phosphorylation of STAT3 (based on molecular weight markers) in LNCaP cells as per antibody 4G10 at a site(s) different from Y705 (Becker et al., 1998) .
Cyclin D1 is a critical cell cycle regulator involved in G 0 /G 1 transition to S phase of the cell cycle (Stacey, 2003) . The data presented in Tables 3 and 4 are consistent with Tkip inhibition of prostate cancer cell cycling in G 0 /G 1 to S transition in DU145 cells and LNCaP cells, respectively. Furthermore, data presented in Figure 2 show that Tkip blocks constitutive and IL-6-induced STAT3 activation on Tyr 705 in the prostate cancer cell lines. It has been reported that phosphorylated or activated STAT3 can enhance cycling D1 expression in cancer cells (Calo et al., 2003) . To determine a possible underlying molecular mechanism for growth inhibition and cell cycle arrest of Tkiptreated prostate cancer cell lines, cells were treated with Tkip at different time points and examined for cyclin D1 expression using Western blot analysis. Tkip treatment caused a modest but definite reduction in cyclin D1 expression in both DU145 (Figure 4a ) and LNCaP cells (Figure 4b ) compared to growth media-treated cells and lipophilic control-treated cells. The fact that STAT3 is not constitutively phosphorylated on Tyr 705, and thus not activated, would suggest that upregulation of cyclin D1 in LNCaP is not caused by activated STAT3. Thus, the modest effects of Tkip on cyclin D1 levels in both DU145 and LNCaP cells would suggest that the inhibitory effects of Tkip at G 0 /G 1 to S of the cell cycle are not due to inhibition of upregulation of cyclin D1. In Figure 3 Tkip reduces tyrosine phosphorylation in (a) DU145 and (b) LNCaP prostate cancer cell lines. Prostate cancer cells were incubated in serum-depleted medium for 20 h and treated with growth medium in the absence or presence of lipophilic Tkip (LipoTkip; 1 mM, 5mM, 8mM) or lipophilic control peptide (LipoMuIFNg(95-125); 8 mM) or IL-6 (10 ng/ml). Specific detection of phosphorylated tyrosine residues was performed by Western blot analysis using the antiphosphotyrosine monoclonal antibody, 4G10 (Upstate Biotechnology, Lake Placid, NY, USA, 1 : 1000). Arrowhead indicates phosphorylated STAT3 expression (top panel). For LNCaP cells, the membrane was stripped and reprobed with antibodies specific for STAT3 phosphorylated at Y705. Membranes were stripped and reprobed with actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA, 1 : 1000) as an internal protein loading control. The results are indicative of two independent experiments Figure 4 Tkip slightly reduces cyclin D1 expression in (a) DU145 and (b) LNCaP prostate cancer cell lines. Cells (2 Â 10 6 ) were incubated in serum-depleted medium for 24 h (T 0 ) and treated in complete growth medium (M) in the presence or absence of lipophilic Tkip (T) or lipophilic MuIFNg(95-125) control (C) peptides for 24 h. Cells were then lysed and protein resolved by SDS-PAGE. Immunoblot analysis was performed with the anticyclin D1 monoclonal antibody (Santa Cruz Biotechnology) according to the manufacturer's instructions. Data are representative of two independent experiments a recent study, it was similarly shown that an EGFR tyrosine kinase inhibitor, ZD1839 (Iressa), blocked G 0 /G 1 to S cell cycle progression of PC-3, DU145, and LNCaP prostate cancer cell lines (Sgambato et al., 2004) . However, in this study it was also shown that ZD1839 treatment did not affect cyclin D1 expression. Given that cell cycle progression was blocked following ZD1839 treatment and that no apparent effect was observed in cyclin D1 expression, the mechanism for EGFR tyrosine kinase inhibition on prostate cancer cell lines remains to be determined. Thus, future studies will examine additional cell cycle regulators to further explore potential molecular processes involved in the observed effects of Tkip-treated prostate cancer cells.
We have previously shown that Tkip is a SOCS-1 mimetic (Flowers et al., 2004) . Tkip binds specifically to the autophosphorylation site of JAK2 and inhibits its autophosphorylation as well as phosphorylation of the IFNg receptor subunit IFNGR-1. Tkip, similar to SOCS-1, also inhibited EGF receptor tyrosine kinase activity, but had no effect on vascular endothelial growth factor receptor or c-src tyrosine kinase activity. Tkip recognition of JAK2 autophosphorylation site is enhanced approximately 10-fold when Y1007 of JAK2 is phosphorylated, which is similar to SOCS-1 recognition of the site.
SOCS-1 induction in several cancers has been shown to be downregulated due to promoter methylation resulting in epigenetic inactivation of the SOCS-1 gene (Chim et al., 2004; Yoshida et al., 2004) . To our knowledge, SOCS-1 induction and/or function in prostate cancers have not been studied. The data presented here with the SOCS-1 mimetic peptide Tkip suggest that SOCS-1 and SOCS-1 mimetics may have potential value in regulation of tyrosine kinases that may be involved in the pathogenesis of prostate cancers.
